P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

For advanced cholangiocarcinoma, standard-of-care first-line systemic treatment is gemcitabine + cisplatin. Activating genetic alterations in patients with intrahepatic cholangiocarcinoma provide potential therapeutic targets. Fibroblast growth factor receptor (FGFR) 2 gene fusions or rearrangements drive cholangiocarcinoma tumorigenesis and occur in 10–16% of patients, being almost exclusively confined to patients with intrahepatic...